Our decellularization technology has realized the high biocompatibility, anti-thrombogenicity, anti-calcification, immune-suppression, as well as enhanced the functionality and durability.
Although the development of medical materials has been advancing steadily, conventional devices still have limitations.
In particular, current implant devices are not only degraded after periods, but also encounter functional deterioration or rupture due to thrombosis, calcification, and inflammatory reaction. Today, developments of novel biomaterials overcoming these problems are expected.
We are researching and developing biomaterials applicable to implantation based upon our own technologies.
Our biomaterials have superiority to conventional medical materials. Moreover, our materials make it possible to reduce thrombosis, calcification, and inflammatory reaction as well as dramatically improve the functions and durability of implant devices.
Our core technology of biomaterials is divided into the following two categories.
1) Technology for decellularization of biological tissues
Our technology has decellularized native tissues without damaging their biological and mechanical properties, suppressing the xenotropic immune responses and cellular infiltration.
Although decellularized biomaterials are ideal for implantation, their practical applications have been hampered by the toxicity of the detergents, insufficient decellularization, and attenuated mechanical strength.
Our technology has overcome the problems related to the decellularization processes, allowing the practical applications into the artificial heart valves and blood vessels.
2) Technology for using biodegradable materials
Our technology have achieved in conventionally used in the medical field. It has also allowed us to develop the reinforcing patches for aortic walls and artificial blood vessels.
Back to main contents
Overcoming the problems related to conventional implant materials, it enables the tissue growth at the implantation sites.